Real-life Use of Niraparib in a Patient Access Program in Norway

Sponsor
Kristina Lindemann
Study ID
NCT04785716
Status
Completed

Conditions

Eligibility Criteria

Sex
FEMALE
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

  • Niraparib — DRUG
    Niraparib provided through the patient access program

Study Details

Retrospective observational study of patients treated with niraparib in an individual patient access program in Norway.

Key Dates

Start date
Jul 31, 2017
Status verified
Mar 2021
Primary completion
Aug 3, 2020
Completion
Aug 3, 2020

Study Design

Enrollment
106 participants (actual)

Primary Outcome Measure

Time to first subsequent treatment [ Time Frame: Through study completion, an average of 15 months ]

Related Studies